// App-Quantinova.ai

890 : A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib to Placebo and to Adalimumab, in Patients with Active Rheumatoid Arthritis with Inadequate Response to Methotrexate

Researchers

Presenter

  • Aileen L. Pangan

Principal Investigators

  • Eduardo Mysler

  • Louis Bessette

  • Charles Peterfy

  • Patrick Durez

  • Andrew Ostor

  • Yihan Li

  • Yijie Zhou

  • Ahmed A. Othman

  • In-Ho Song

  • Mark C. Genovese

Medical Centers

  • Southwestern Medical Center at Dallas Metroplex Clinical Research Center, Dallas, United States

  • AbbVie, Inc., North Chicago, IL

  • Organizacion Medica de Investigacion, Buenos Aires, Argentina

  • Laval University, Quebec, Quebec, Canada.

  • Spire Sciences, Inc., Boca Raton, FL

  • Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique, Bruxelles, Belgium

  • Cabrini Medical Centre, Malvern, Australia

  • AbbVie, Inc., North Chicago, IL

  • Stanford University Medical Center, Palo Alto, CA

Locations

  • United States

  • Argentina

  • Canada

  • Belgium

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Methotrexate

  • ABT-494

  • Adalimumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved